Skip to content Carb-X
Carb-X
Boston University
Mobile Menu Toggle navigation
  • Sign Up
  • Contact
  • Twitter
  • LinkedIn
Carb-X
Boston University
Boston University
  • About CARB-X
    • Overview
    • Global Threat
    • Our Strategy
    • Stewardship and Access
    • Management & Staff
    • Joint Oversight Board
    • Advisory Board
    • Careers
    • Annual Reports
    • Boston University
  • Portfolio
    • Portfolio Product Developers
    • Portfolio-Pipeline
    • CARB-X Graduates
    • Spotlight on Science
    • Portfolio Acceleration Tools
  • Partners
    • Funding Partners
    • Global Accelerator Network
  • Apply
    • Funding Themes
    • Omnibus Solicitation
    • Application Process
    • Entering Portfolio
    • Apply Here
    • Applicant Questions
  • Resources
    • CARB-X Connect
    • Presentations
    • Videos
    • Publications
    • Education
    • PD Resources
    • Media Resources
  • News
    • CARB-X News
    • In the News
    • Antibiotic Resistance
  • Events
  • About CARB-X
    • Overview
    • Global Threat
    • Our Strategy
    • Stewardship and Access
    • Management & Staff
    • Joint Oversight Board
    • Advisory Board
    • Careers
    • Annual Reports
    • Boston University
  • Portfolio
    • Portfolio Product Developers
    • Portfolio-Pipeline
    • CARB-X Graduates
    • Spotlight on Science
    • Portfolio Acceleration Tools
  • Partners
    • Funding Partners
    • Global Accelerator Network
  • Apply
    • Funding Themes
    • Omnibus Solicitation
    • Application Process
    • Entering Portfolio
    • Apply Here
    • Applicant Questions
  • Resources
    • Presentations
    • Videos
    • Publications
    • Education
    • PD Resources
    • Media Resources
  • News
    • CARB-X News
    • In the News
    • Antibiotic Resistance
  • Events
  • Contact
  • Legal

Portfolio Company

  • Portfolio
  • >
  • Gallery
Centauri Therapeutics

Centauri Therapeutics, Sandwich, UK
www.centauritherapeutics.com/

ABX01
NOVEL LARGE MOLECULE ANTIBACTERIAL

Duel-acting Immunotherapy

Centauri Therapeutics is developing novel immunotherapies, leveraging its proprietary Alphamer™ platform which re-directs existing polyclonal antibodies to address indications of high unmet need, including hard-to-treat bacterial infections. With CARB-X support, Centauri will continue development of its lead program, ABX01. ABX01 targets drug-sensitive and multi-drug resistant (MDR) Gram-negative bacteria, including clinically-relevant strains of Enterobacteriaceae, P. aeruginosa, and A. baumannii. The novel features of this approach are: an ability to harness and re-direct pre-existing and naturally occurring effector antibodies; broad spectrum efficacy against Gram-negative bacterial infections; and direct and immune-mediated mechanism of bacterial killing

Current Development Stage: Lead Optimization

CARB-X Investment: Initial investment of up to $1.4m

Initial CARB-X Investment Date: December 1, 2019

Carb-X

Led by Boston University

Copyright 2023

  • Contact
  • Careers
  • Site Credits
  • Legal
  • Twitter
  • LinkedIn

Copyright 2023